YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China. It also man…
Drug Manufacturers - Specialty & Generic
CN, Yichang [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 100.00 | 5.59 | 0.00 | |
| Graham Fair Price | 100.00 | 14.84 | 0.00 | |
| PEG | -100.00 | -0.28 | 0.00 | |
| Price/Book | 100.00 | 0.94 | 0.00 | |
| Price/Cash Flow | 100.00 | 24.80 | 0.00 | |
| Prices/Earnings | 100.00 | 1.93 | 0.00 | |
| Price/Sales | 100.00 | 2.41 | 0.00 | |
| Price/FCF | 100.00 | 24.80 | 0.00 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 100.00 | 0.78 | 0.00 | |
| Operating Margin | 100.00 | 0.42 | 0.00 | |
| ROA | n.A. | 0.08 | n.A. | |
| ROE | n.A. | 0.12 | n.A. | |
| ROIC | n.A. | 0.12 | n.A. | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.42 | 0.00 | -100.00 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.00 | -0.12 | -100.00 | |
| EPS QOQ | 0.00 | -0.07 | -100.00 | |
| FCF QOQ | 0.00 | -0.71 | -100.00 | |
| Revenue QOQ | 0.00 | -0.04 | -100.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 55.46 | 100.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 60.45 | 100.00 | |
| Inventory Turnover | n.A. | 1.62 | n.A. | |
| Debt/Capitalization | 0.39 | 0.25 | -37.06 | |
| Quick Ratio | 0.67 | 0.87 | 29.39 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Bad
Fundamentals
Per Share Metrics
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | 8.98 | 100.00 | |
| Cash | 0.00 | 1.92 | 100.00 | |
| Capex | 0.00 | -0.15 | -100.00 | |
| Free Cash Flow | 0.00 | 0.34 | 100.00 | |
| Revenue | 0.00 | 3.49 | 100.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Best
Fundamentals
Financial Health
06 - Financial Health ·
Weak